Skip to main content

Table 4 Occurrence of common toxicities

From: The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902)

Toxicity

Induction therapy

CapeOX + BEV

(N = 52)

Maintenance therapy

Capecitabin + BEV

(N = 45)

Reintoroduction therapy

CapeOX + BEV

(N = 29)

All grade

≥Grade 3

All grade

≥Grade 3

All grade

≥Grade 3

n

%

n

%

n

%

n

%

n

%

n

%

Hematologic toxiciy

20

38.5

5

9.6

12

26.7

3

6.7

11

37.9

2

6.9

 Neutropenia

10

19.2

4

7.7

4

8.9

2

4.4

4

13.8

2

6.9

 Thrombocytopenia

9

17.3

0

0

8

17.8

1

2.2

8

27.6

0

0

 Anemia

9

17.3

0

0

4

8.9

0

0

3

7.1

0

0

 Febrile neutropenia

1

1.9

1

1.9

0

0

0

0

0

0

0

0

Non-hematologic toxicity

44

84.6

8

15.4

36

80.0

6

13.3

22

75.9

6

20.7

 Diarrhea

7

13.5

1

1.9

2

4.4

0

0

2

6.9

0

0

 Nausea/vomiting

8

15.4

0

0

2

4.4

0

0

3

10.3

0

0

 Mucositis

8

15.4

0

0

2

4.4

0

0

2

6.9

0

0

 Hand-foot syndrome

33

63.5

1

1.9

22

48.9

4

8.9

16

55.2

3

10.3

 Fatigue

0

0

0

0

1

2.2

0

0

1

3.4

0

0

 Peripheral neuropathy

26

50.0

1

1.9

17

37.8

0

0

14

48.3

2

6.9

 Allergy

2

3.8

1

1.9

0

0

0

0

3

10.3

2

6.9

BEV-related toxicities

14

26.9

1

1.9

17

37.8

1

2.2

11

37.9

1

3.4

 Hypertension

9

17.3

0

0

11

24.4

0

0

8

27.6

0

0

 Proteinuria

6

11.5

0

0

5

11.1

0

0

3

10.3

1

3.4

 Bleeding

0

0

0

0

0

0

0

0

1

3.4

0

0

 Infection

1

1.9

0

0

2

4.4

1

2.2

1

3.4

0

0

 Thrombosis

1

1.9

1

1.9

0

0

0

0

0

0

0

0

  1. BEV bevacizumab, N total number of patients, n number of patients